Current status and perspective of antiangiogenic therapy for cancer: urinary cancer

Kanda, Shigeru; Miyata, Yasuyoshi; Kanetake, Hiroshi

doi:10.1007/s10147-006-0565-6

Cited by 13 publications

(5 citation statements)

References 241 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The critical issue that remains is the therapeutic impact of VEGF and its receptors. Anti-angiogenic agents include humanised neutralising anti-VEGF monoclonal antibodies, receptor antagonists, soluble receptors, antagonistic VEGF mutants and inhibitors of VEGF receptor function (16). Antiangiogenic therapy has been shown to be effective in some variants of tumors, although its effectiveness in PCa remains to be clarified.…”

Section: Discussionmentioning

confidence: 99%

The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy

Mao

Camparo²,

Badoual³

et al. 2008

Oncol Rep

View full text Add to dashboard Cite

In the current study, we analysed the prognostic value of vascular endothelial growth factor receptor-1 (VEGFR-1) in clinically-localized prostate cancer (PCa). Forty patients who had undergone radical prostatectomy (RP) for clinically-localized PCa were included. Two groups were compared: 17 patients who experienced cancer progression following RP (group 1) and 23 patients who remained free of recurrence after intervention (group 2). Paraffin-embedded sections obtained from the RP specimens of the 40 patients were used to build tissue microarrays. The expression of VEGFR-1 was examined in the RP specimens using immunohistochemistry and was compared between the groups of patients. The two groups had similar tumor characteristics in terms of PSA, Gleason score and pathological stage of cancer. The median intensity score of VEGFR-1 expression was significantly higher in pT3 tumors than in pT2 tumors. Nevertheless, the intensity scores of VEGFR-1 expression were similar in the two groups of patients. Our results suggest that VEGFR-1 expression is not associated with the risk of cancer progression following RP. Therefore, VEGFR-1 may not be of prognostic value in clinically-localized PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy

Mao

Camparo²,

Badoual³

et al. 2008

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Inhibitors targeting other protein-tyrosine kinase and serine/ threonine kinase targets have been investigated as possible antiangiogenic therapies (62,63). Although they showed potent antiangiogenic activities and subsequent tumor regression in preclinical models, many of them failed to regress pre-existing tumors or improve survival in human clinical trials.…”

Section: Roles Of Src Family Kinases In Angiogenesismentioning

confidence: 99%

Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review)

Kanda

Miyata²,

Kanetake³

et al. 2007

Int J Mol Med

Self Cite

View full text Add to dashboard Cite

“…Currently, the most widely studied prognostic factors are related to pathologic characteristics of the neoplasm, including tumor size, grade, stage, and vascular invasion (29)(30)(31)(32).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non–Muscle-Invasive Bladder Cancer

Puntoni

Petrera

Campora

et al. 2016

Cancer Prevention Research

View full text Add to dashboard Cite

Non–muscle-invasive bladder cancer (NMIBC) may progress to muscle-invasive disease, but no effective preventive treatments are available. In addition, no reliable prognostic biomarkers have been identified. We assessed the long-term effect of the oral retinoid fenretinide and the prognostic value of circulating VEGF levels. We updated through the Tumor Registry the vital status of 99 patients with resected Ta/T1 bladder tumors who were recruited in a randomized trial of 2 years of fenretinide or no treatment in 1993–1994. Serum VEGF levels measured at baseline and 12 months were available in a subgroup of 62 patients. After a median of 20.5 years, 54 subjects died, 35 of any cancer and 14 of bladder cancer. Neither overall survival (OS), nor cancer survival (CS) or bladder cancer survival (BCS) was affected by fenretinide (log-rank P ≥ 0.2). DNA aneuploidy in bladder washing was associated with shorter OS (P = 0.02), CS (P = 0.05), and BCS (P = 0.09). Subjects with baseline VEGF levels in the top quintile (≥350 pg/mL) had a significantly shorter OS (P = 0.01), CS (P = 0.02), and BCS (P = 0.008). The trend across quintiles of VEGF was significant for BCS (P = 0.007). Multivariate analyses showed that, in addition to smoking status, VEGF level in the top quintile was an independent prognostic factor for OS (HR = 2.7; 95% CI, 1.1–6.5), CS (HR = 3.3; 95% CI, 1.1–9.4) and BCS (HR = 8.9; 95% CI,1.3–61). Fenretinide did not affect the long-term outcome of patients with NMIBC. High serum VEGF level was a significant predictor of overall and cancer death and may help to identify high-risk subjects who may benefit from a preventive therapy. Cancer Prev Res; 9(6); 437–44. ©2016 AACR.

show abstract

Current status and perspective of antiangiogenic therapy for cancer: urinary cancer

Cited by 13 publications

References 241 publications

The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy

The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy

Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review)

Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non–Muscle-Invasive Bladder Cancer

Contact Info

Product

Resources

About